Vasculitis & polymyalgia rheumatica

Azathioprine vs methotrexate in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective study

Rheumatology (Oxford)Published Retrospective cohort study

Authors' conclusion

A significant proportion of patients achieved remission with both MTX and AZA. MTX1 had an earlier remission on a lower GC dose but MTX2 had a better steroid-sparing effect.

Study context

Population
Patients with EGPA treated with AZA or MTX, single centre4 treatment groups
Participants
57 patients
Exposure
MTX vs AZA as first-line agents in non-severe disease or as second-line maintenance after CYC/rituximab in severe disease
Outcome
Remission rate R1 (BVAS = 0)
Follow-up
First 5 years of treatment
Methodological detailsmonocentric
  • Monocentric

Main finding

As reported in the abstract

MTX1 vs AZA1: P = 0.53 · MTX2 vs AZA2: P = 0.23

Observational data: associations, not effects.

Further findings

OutcomeMTX1AZA1MTX2AZA2P value
Remission R2 (BVAS = 0 with prednisone ≤5 mg/day) · first 6 monthsMTX1 vs AZA154%12%— not stated in the abstract— not stated in the abstractP = 0.04
Remission R3 (MIRRA: BVAS = 0 with prednisone ≤3.75 mg/day) · up to first 18 monthsMTX1 vs AZA135%0 events— not stated in the abstract— not stated in the abstractP = 0.07
Cumulative GC dose · 5 yearsMTX2 vs AZA2— not stated in the abstract— not stated in the abstract6 g10.7 gP = 0.03
Asthma/ENT relapsesAZA2 vs MTX2— not stated in the abstract— not stated in the abstract64%23%P = 0.04

— not stated in the abstract

Time-to-first relapse

No differences emerged in time-to-first relapse

Safety

Adverse events

P = 0.004

Adverse events

Without affecting the suspension rate

Original publication

Azathioprine vs methotrexate in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective study. Rheumatology (Oxford). Published 16 June 2023. doi:10.1093/rheumatology/kead302

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.